Related Experiment Video
Updated: Mar 25, 2026
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma
Youngkyu Moon1, Sook Whan Sung1, Kyo Young Lee2
1Department of Thoracic & Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.
Background:
Stage I pulmonary adenocarcinoma (PA) can offer an unfavorable prognosis. The aim of this study was to classify the prognosis of stage I PA on the basis of the lepidic component and to confirm whether the lepidic component can be used as a criterion for predicting the prognosis of stage I PA.
Methods:
We conducted a retrospective study of patients who underwent curative surgery for stage I and IIA PA. Stage I disease was divided into three groups on the basis of the lepidic component: group 1, ≤10%; group 2, >10 to 50%; and group 3, >50%. We compared recurrence-free survival (RFS) rates among groups 1, 2, and 3, and stage IIA disease. We also evaluated risk factors for disease recurrence with multivariate analysis.
Results:
A total of 224 patients were included in our study; most patients (n=201) had stage I disease. Three-year RFS rates in group 1 (n=73), group 2 (n=75), and group 3 (n=53) were 74.1, 90.4, and 90.0%, respectively. There was a significant difference in RFS between group 1 and group 2 (p=0.009). The 3-year RFS rate in stage IIA disease was 61.4%. There were no significant differences in RFS between group 1 and stage IIA disease (p=0.163). In multivariate analysis, group 1 had the highest risk of recurrence (HR 5.806, p=0.006) in stage I PA.
Conclusions:
Stage I PA with a lepidic component≤10% was associated with an unfavorable prognosis that was similar to the prognosis of stage IIA disease. The prognosis for stage I PA should not be based on general criteria, but instead, the lepidic component should be evaluated and considered when determining disease prognosis.
